You are trying to reach document intended for healthcare professionals only
Letters to HCPs
Beovu ▼ (brolucizumab) – Dear Healthcare Professional Communication
For Healthcare Professionals
DHPC describing the updated recommendations to minimise the known risk of intraocular inflammation, including retinal vasculitis and/or retinal vascular occlusion.